Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis
| Autor: | Héliton Spíndola Antunes, Daniel Herchenhorn, Gabriela de Assis Ramos, Fernando Luiz Dias, Celia Maria Pais Viégas, Isabele Avila Small, Carlos Gil Ferreira, Carlos M.M. Araújo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Mucositis Humans Medicine Progression-free survival Low-Level Light Therapy Low level laser therapy Cisplatin Stomatitis Chemotherapy business.industry Head and neck cancer Chemoradiotherapy 030206 dentistry Middle Aged medicine.disease Survival Analysis Surgery Radiation therapy Oncology Head and Neck Neoplasms 030220 oncology & carcinogenesis Female Oral Surgery business medicine.drug |
| Zdroj: | Oral Oncology. 71:11-15 |
| ISSN: | 1368-8375 |
| Popis: | Background The impact of low-level laser therapy (LLLT) to prevent oral mucositis in patients treated with exclusive chemoradiation therapy remains unknown. This study evaluated the overall, disease-free and progression-free survival of these patients. Methods: Overall, disease-free and progression-free survival of 94 patients diagnosed with oropharynx, nasopharynx, and hypopharynx cancer, who participated on a phase III study, was evaluated from 2007 to 2015. The patients were subjected to conventional radiotherapy plus cisplatin every 3 weeks. LLLT was applied with an InGaAlP diode (660 nm–100 mW–1 J–4 J/cm 2 ). Results With a median follow-up of 41.3 months (range 0.7–101.9), patients receiving LLLT had a statistically significant better complete response to treatment than those in the placebo group (LG = 89.1%; PG = 67.4%; p = 0.013). Patients subjected to LLLT also displayed increase in progression-free survival than those in the placebo group (61.7% vs. 40.4%; p = 0.030; HR:1:93; CI 95%: 1.07–3.5) and had a tendency for better overall survival (57.4% vs. 40.4%; p = 0.90; HR:1.64; CI 95%: 0.92–2.91). Conclusion This is the first study to suggest that LLLT may improve survival of head and neck cancer patients treated with chemoradiotherapy. Further studies, with a larger sample, are necessary to confirm our findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect